1. Scrip
  2. >>Focus On Asia
  3. >>China

Henlius Forges Ahead With US PD-1 Plans Despite Peers' Setbacks

Bridging Study Planned

 
• By Dexter Jie Yan

The latest step by the Chinese drug maker to support its international ambitions is a bridging study in the US, which will evaluate its PD-1 contender serplulimab against Roche’s PD-L1-targeted Tecentriq.

US PD-1 market
Like its compatriots, Henlius can't resist lure of the US market • Source: Shutterstock

Hong Kong-listed Shanghai Henlius Biotech Co. Ltd. is set to renew Chinese biotechs’ efforts to land an immuno-oncology antibody onto the US market, with a regulatory pathway now set for its anti-PD-1 drug serplulimab (HLX10, already marketed as Hansizhuang in China).

Since its inception as a biologics arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.